What is the history of Tracheobronchomalacia?

Tracheobronchomalacia (TBM) was first clinically identified in the mid-20th century as physicians began to differentiate airway collapse from other obstructive lung diseases. Historically misdiagnosed as asthma or chronic obstructive pulmonary disease (COPD), our understanding of Tracheobronchomalacia has evolved from simple observation to high-resolution dynamic imaging that allows for precise surgical and non-surgical management.

When was Tracheobronchomalacia first identified?

The medical literature began to formally recognize Tracheobronchomalacia in the 1950s and 1960s, notably through the work of researchers like Dr. K.H. Hertzog, who described the collapse of the tracheal wall. Early reports often labeled the condition as "tracheal collapse" or "flaccid trachea," primarily observed during autopsy or rudimentary bronchoscopy. For decades, many patients were mismanaged because the condition was viewed as a secondary symptom rather than a primary clinical entity.

How has our understanding of Tracheobronchomalacia evolved?

The evolution of Tracheobronchomalacia diagnosis moved from static X-rays—which often missed the dynamic collapse—to modern dynamic expiratory CT scans and fiber-optic bronchoscopy. These advancements confirmed that Tracheobronchomalacia is defined by the excessive expiratory collapse of the airway, often exceeding 50% of the cross-sectional area. Today, we recognize both primary (congenital) and secondary (acquired) forms, with the latter often resulting from chronic inflammation or mechanical ventilation.

What are the major milestones in treating Tracheobronchomalacia?

Treatment for Tracheobronchomalacia has transitioned from conservative, symptom-based management to targeted interventions. Key milestones include:

• 1970s-80s: Introduction of internal and external stenting to provide structural support to the airway.


• 1990s: Development of tracheobronchoplasty, a surgical technique to stabilize the posterior membrane.


• 2010s-Present: Integration of 3D-printed bioresorbable splints for pediatric cases, marking a shift toward personalized medicine.

How has patient advocacy changed the landscape?

For years, individuals with Tracheobronchomalacia felt isolated due to the rarity of their diagnosis. Through platforms like DiseaseMaps.org, where 41 community members currently share their experiences, patients have moved from "medical mysteries" to active participants in their care. This collective advocacy has pushed for better clinical guidelines and increased awareness among pulmonologists, ensuring that Tracheobronchomalacia is considered earlier in the diagnostic process for patients with persistent, treatment-resistant coughs.

Next steps

• Consult with a specialized pulmonologist or thoracic surgeon experienced in dynamic airway pathology.


• Request a dynamic expiratory CT scan if TBM is suspected.


• Join the DiseaseMaps.org community to connect with other patients and share experiences.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Portal for rare diseases and orphan drugs


• PubMed: Clinical studies on tracheobronchoplasty and airway dynamics


• OMIM (Online Mendelian Inheritance in Man)